Jennifer Burdman

Managing Director at Sauvegarder Investment Management

Speaker

Jennifer Burdman served as the Chief IP Officer and Deputy General Counsel at Valo Health, overseeing the company's IP strategy and advising leadership on IP-related matters. Her tenure has seen significant developments, such as the noted licensing deal with Novo Nordisk and the acquisition of Tara Biosystems, which brought in the Biowire advanced tissue engineering and disease modeling tech. Prior to going in-house, as a trial lawyer, her noteworthy cases included a jury verdict of patent infringement resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets with damages of over $900 million, and the successful defense of a university against a licensee seeking expanded rights of sponsored research and license agreements. She was recognized as one of 2020's "Top 25 Women Leaders in Biotechnology" by The Healthcare Technology Report.